Date: 2017-01-27
Type of information: Grant
Company: PCI Biotech (Norway)
Investors: the Research Council of Norway (Norway)
Amount: NOK 13.8 million
Funding type: grant
Planned used:
- The grant from The Research Council of Norway will support the project "Photochemical vaccination - novel immunotherapy concept for treatment of cancer and infectious diseases". The main goal of the project is to document in a proof-of-principle clinical study in cancer patients that PCI Biotech's photochemical internalization (PCI) technology can be used to improve the efficacy of a therapeutic cancer vaccine. Other important aspects of the project is to develop the PCI technology for use in vaccination against certain types of viral and bacterial infections, and to explore the technology for use with mRNA-based vaccination.
Others:
- • On January 27, 2017, PCI Biotech announced that it has been awarded NOK 13.8 million in a BIA grant from The Research Council of Norway to the project "Photochemical vaccination - novel immunotherapy concept for treatment of cancer and infectious diseases". The project will be initiated in Q3 2017 and run for three and a half years. The grant will cover up to 35% of the project costs and the project will be implemented in the company's current plans. The grant is subject to final contract negotiations.
Therapeutic area: Cancer - Oncology
Is general: Yes
